Immunology/Immunotherapy

免疫系统既是恶性肿瘤的来源，也是癌症治疗的工具。的 免疫学/免疫治疗计划（IMM）支持基础和临床研究，以增加 理解和控制（1）对癌症的免疫反应和（2）造血细胞 发育及其失调可用于治疗恶性血液病。IMM计划成员 通过三个科学主题来实现这一双重目标：（1）发展和优化 抗原导向的免疫治疗;（2）抗肿瘤质量的正负调控 免疫力(3)控制造血和血液肿瘤。这些主题包括杰出的 基础科学研究，以及高度合作的转化计划，以开发临床试验 基于这项研究。项目共同负责人，维克托恩格尔哈德，博士，是国际公认的工作 在肿瘤抗原鉴定和诱导肿瘤特异性CD 8 T细胞应答中的应用。项目共同负责人， 克雷格Slingluff，医学博士，作出了重大贡献，癌症免疫治疗，通过两个实验室研究 和药物诱导的临床试验。该计划由27名正式成员和3名准成员组成 来自医学院的六个系该计划的校外资金总额超过17美元 其中包括来自国家癌症研究所（NCI）的400万美元。项目组成员293人 癌症相关出版物，其中21%是计划间出版物，19%是计划内出版物， 最后一次更新。该计划支持研究进展介绍和研讨会，以产生新的 提供试点资金，鼓励发展有前途的合作和想法; 以及免疫监测实验室，以促进临床研究。17例患者启动的临床 由项目成员领导的试验，包括两项ECOG试验和另外三项多中心试验， 招募了六种癌症组织学类型的患者，并评估了肽疫苗、细胞因子和抗体。 这些试验测试实验室科学产生的假设，也给实验室带来了裂痕， 研究细胞过程和分子机制来解释临床发现。这个程序 提供了一个坚实的基础，在这两个confinued进步的理解免疫系统和 这些知识可以改善免疫疗法和血液恶性肿瘤的治疗。

The immune system is both a source of malignancies and a tool for cancer therapy. The Immunology/lmmunotherapy Program (IMM) supports basic and clinical research to increase the understanding and control of (1) the immune response to cancer and (2) the ways hematopoiefic cell development and its dysregulation can be used to treat hematologic malignancies. IMM Program members approach this two-faceted goal through three scientific Themes: (1) Development and Opfimizafion of Antigen-Directed Immunotherapeutics; (2) Positive and Negative Regulation of the Quality of Anti-Tumor Immunity. (3) Control of Hematopoiesis and Hematologic Malignancies. These Themes include outstanding basic science investigations, as well as highly collaborative translational initiatives to develop clinical trials based on this research. Program Co-Leader, Victor Engelhard, PhD, is internationally recognized for his work in tumor antigen identificafion and inducfion of tumor-specific CD8 T cell responses. Program Co-leader, Craig Slingluff, MD, has made major contribufions to cancer immunotherapy through both laboratory research and investigator-inifiated clinical trials. The Program consists of 27 Full Members and 3 Associate Members from six departments in the School of Medicine. Total extramural funding for the Program exceeds $17 million, including $4 million from the National Cancer Institute (NCI). Program Members have produced 293 cancer-relevant publications, of which 21% were inter-programmatic and 19% were intra-programmafic since the last renewal. The Program supports research in progress presentations and seminars to engender new direcfions and collaborafions; Pilot funding to encourage development of promising collaborations and ideas; and an Immune Monitoring Laboratory to facilitate clinical research. Seventeen investigator-initiated clinical trials led by Program Members, including hwo ECOG trials and three additional multicenter trials, have enrolled patients across six cancer histologies and evaluated pepfide vaccines, cytokines, and antibodies. These trials test hypotheses arising from laboratory science and also bring fissue to the laboratories to invesfigate cellular processes and molecular mechanisms to explain the clinical findings. This Program provides a firm foundation for confinued advances in both understanding of the immune system and ufilizing that knowledge to improve immunotherapy and treatment of hematologic malignancies.